290 related articles for article (PubMed ID: 32487734)
21. A p300 and SIRT1 Regulated Acetylation Switch of C/EBPα Controls Mitochondrial Function.
Zaini MA; Müller C; de Jong TV; Ackermann T; Hartleben G; Kortman G; Gührs KH; Fusetti F; Krämer OH; Guryev V; Calkhoven CF
Cell Rep; 2018 Jan; 22(2):497-511. PubMed ID: 29320743
[TBL] [Abstract][Full Text] [Related]
22. HIPK2 modulates p53 activity towards pro-apoptotic transcription.
Puca R; Nardinocchi L; Sacchi A; Rechavi G; Givol D; D'Orazi G
Mol Cancer; 2009 Oct; 8():85. PubMed ID: 19828042
[TBL] [Abstract][Full Text] [Related]
23. Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2.
Goodfellow GH; Dupret JM; Grant DM
Biochem J; 2000 May; 348 Pt 1(Pt 1):159-66. PubMed ID: 10794727
[TBL] [Abstract][Full Text] [Related]
24. Knockout of human arylamine N-acetyltransferase 1 (NAT1) in MDA-MB-231 breast cancer cells leads to increased reserve capacity, maximum mitochondrial capacity, and glycolytic reserve capacity.
Carlisle SM; Trainor PJ; Doll MA; Stepp MW; Klinge CM; Hein DW
Mol Carcinog; 2018 Nov; 57(11):1458-1466. PubMed ID: 29964355
[TBL] [Abstract][Full Text] [Related]
25. Phenotype of the most common "slow acetylator" arylamine N-acetyltransferase 1 genetic variant (NAT1*14B) is substrate-dependent.
Millner LM; Doll MA; Cai J; States JC; Hein DW
Drug Metab Dispos; 2012 Jan; 40(1):198-204. PubMed ID: 22010219
[TBL] [Abstract][Full Text] [Related]
26. CBP/p300 acetyltransferase activity in hematologic malignancies.
Dutta R; Tiu B; Sakamoto KM
Mol Genet Metab; 2016 Sep; 119(1-2):37-43. PubMed ID: 27380996
[TBL] [Abstract][Full Text] [Related]
27. Genome-wide profiling of H3K56 acetylation and transcription factor binding sites in human adipocytes.
Lo KA; Bauchmann MK; Baumann AP; Donahue CJ; Thiede MA; Hayes LS; des Etages SA; Fraenkel E
PLoS One; 2011; 6(6):e19778. PubMed ID: 21655096
[TBL] [Abstract][Full Text] [Related]
28. Population variability of rhesus macaque (Macaca mulatta) NAT1 gene for arylamine N-acetyltransferase 1: Functional effects and comparison with human.
Boukouvala S; Chasapopoulou Z; Giannouri D; Kontomina E; Marinakis N; Rizou SV; Stefani I; Tsirka T; Veyssière C; Zaliou S; Sabbagh A; Crouau-Roy B; Fakis G
Sci Rep; 2019 Jul; 9(1):10937. PubMed ID: 31358821
[TBL] [Abstract][Full Text] [Related]
29. Structure and regulation of the drug-metabolizing enzymes arylamine N-acetyltransferases.
Dupret JM; Rodrigues-Lima F
Curr Med Chem; 2005; 12(3):311-8. PubMed ID: 15723621
[TBL] [Abstract][Full Text] [Related]
30. Differences between murine arylamine N-acetyltransferase type 1 and human arylamine N-acetyltransferase type 2 defined by substrate specificity and inhibitor binding.
Laurieri N; Kawamura A; Westwood IM; Varney A; Morris E; Russell AJ; Stanley LA; Sim E
BMC Pharmacol Toxicol; 2014 Nov; 15():68. PubMed ID: 25432241
[TBL] [Abstract][Full Text] [Related]
31. Redox regulation of the human xenobiotic metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1). Reversible inactivation by hydrogen peroxide.
Atmane N; Dairou J; Paul A; Dupret JM; Rodrigues-Lima F
J Biol Chem; 2003 Sep; 278(37):35086-92. PubMed ID: 12832400
[TBL] [Abstract][Full Text] [Related]
32. Multiple histone deacetylases and the CREB-binding protein regulate pre-mRNA 3'-end processing.
Shimazu T; Horinouchi S; Yoshida M
J Biol Chem; 2007 Feb; 282(7):4470-4478. PubMed ID: 17172643
[TBL] [Abstract][Full Text] [Related]
33. Acetylation of lysine 109 modulates pregnane X receptor DNA binding and transcriptional activity.
Pasquel D; Doricakova A; Li H; Kortagere S; Krasowski MD; Biswas A; Walton WG; Redinbo MR; Dvorak Z; Mani S
Biochim Biophys Acta; 2016 Sep; 1859(9):1155-1169. PubMed ID: 26855179
[TBL] [Abstract][Full Text] [Related]
34. Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1.
Zhu Y; Hein DW
Pharmacogenomics J; 2008 Oct; 8(5):339-48. PubMed ID: 17909564
[TBL] [Abstract][Full Text] [Related]
35. Genetic and small molecule inhibition of arylamine N-acetyltransferase 1 reduces anchorage-independent growth in human breast cancer cell line MDA-MB-231.
Stepp MW; Doll MA; Carlisle SM; States JC; Hein DW
Mol Carcinog; 2018 Apr; 57(4):549-558. PubMed ID: 29315819
[TBL] [Abstract][Full Text] [Related]
36. Role for human arylamine N-acetyltransferase 1 in the methionine salvage pathway.
Witham KL; Minchin RF; Butcher NJ
Biochem Pharmacol; 2017 Feb; 125():93-100. PubMed ID: 27865712
[TBL] [Abstract][Full Text] [Related]
37. Recombinant rat and hamster N-acetyltransferases-1 and -2: relative rates of N-acetylation of arylamines and N,O-acyltransfer with arylhydroxamic acids.
Jones RF; Land SJ; King CM
Carcinogenesis; 1996 Aug; 17(8):1729-33. PubMed ID: 8761433
[TBL] [Abstract][Full Text] [Related]
38. Arylamine N-acetyltransferase I.
Minchin RF; Hanna PE; Dupret JM; Wagner CR; Rodrigues-Lima F; Butcher NJ
Int J Biochem Cell Biol; 2007; 39(11):1999-2005. PubMed ID: 17392017
[TBL] [Abstract][Full Text] [Related]
39. Effect of nucleotide substitutions in N-acetyltransferase-1 on N-acetylation (deactivation) and O-acetylation (activation) of arylamine carcinogens: implications for cancer predisposition.
Fretland AJ; Doll MA; Zhu Y; Smith L; Leff MA; Hein DW
Cancer Detect Prev; 2002; 26(1):10-4. PubMed ID: 12088197
[TBL] [Abstract][Full Text] [Related]
40. Placental expression of arylamine N-acetyltransferases: evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2.
Smelt VA; Mardon HJ; Sim E
Pharmacol Toxicol; 1998 Oct; 83(4):149-57. PubMed ID: 9820875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
